Last updated: February 24, 2026
What Is the Current Status of NDC 66758-0145?
NDC 66758-0145 is a prescription drug approved by the U.S. Food and Drug Administration (FDA) with specific indications and formulations. This NDC code refers to a monoclonal antibody therapy approved for treatment in certain autoimmune diseases. The drug entered the market in early 2022.
The drug’s manufacturer is a leading biotech company with a focus on targeted biologic therapies. Its approval is based on phase III clinical trials demonstrating comparable efficacy and safety to existing therapies.
What Is the Market Size for This Therapeutic Area?
The therapeutic class primarily serves patients with autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Estimated Market Data (2022-2027):
| Year |
Estimated US Market (USD billions) |
Compound Annual Growth Rate (CAGR) |
| 2022 |
8.2 |
— |
| 2023 |
9.1 |
11% |
| 2024 |
10.2 |
12% |
| 2025 |
11.4 |
11% |
| 2026 |
12.7 |
11.4% |
| 2027 |
14.2 |
11.5% |
The growth is driven by increasing prevalence of autoimmune diseases and expanded indications for monoclonal antibody therapies.
Competitive Landscape
The primary competitors include established biologics such as adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). Additionally, newer agents like risankizumab and guselkumab are gaining market share.
What Are the Key Price Factors?
Pricing is influenced by several factors:
- Market exclusivity: Patents provide exclusivity for approximately 10-12 years.
- Manufacturing complexity: Biologics tend to have high production costs.
- Competition level: Lower if the product is first-in-class or has a novel mechanism.
- Pricing benchmarks: Based on existing biologics in the same class, ranging from $5,000 to $7,500 per month for the approved indications.
What Are the Current Price Projections?
Initial Launch Price
Upon initial entry, the monthly treatment price is estimated between $6,000 and $7,000, consistent with similar biologics.
Market Penetration and Price Trajectory
| Year |
Projected Wholesale Price (USD/month) |
Notes |
| 2022 |
$6,500 |
Launch price, with insurers negotiating discounts. |
| 2023 |
$6,300 |
Slight decrease due to payor negotiations. |
| 2024 |
$6,100 |
Market saturation lowers price pressure. |
| 2025 |
$6,000 |
Stabilizes as brand recognition stabilizes. |
| 2026 |
$5,900 |
Slight reduction aligned with generics and biosimilars. |
Discounting and Reimbursement Trends
Reimbursement discounts can range from 10-25% based on formulary placements and payer negotiations. Biosimilar entry expected by 2028 could further pressure prices downward.
What Does Future Pricing Look Like With Biosimilars?
Forecasts suggest biosimilar competition by 2028 will lead to a 35-50% reduction in biologic prices for this class. The anticipated biosimilar pricing would likely be between $3,000 and $4,000 per month.
How Will Market Dynamics Impact Pricing?
- Biosimilar entry reduces average biologic prices.
- Increased competition results in more aggressive discounts offered to payors.
- Regulatory pressures and value-based pricing models could further influence price caps.
Summary of Key Metrics
| Metric |
Details |
| Price at Launch |
$6,500/month |
| Expected 2025 Price |
$6,000/month |
| Biosimilar Entry |
Expected 2028 |
| Biosimilar Price Range |
$3,000 - $4,000/month |
| Market CAGR (2022-2027) |
11.3% |
Key Takeaways
- NDC 66758-0145 targets a lucrative, growing autoimmune therapy segment.
- Initial pricing aligns with existing biologics, around $6,500/month.
- Competition and biosimilar entry will exert downward pressure on prices.
- Market size projected to reach $14.2 billion by 2027, with steady growth.
- Long-term price reductions are expected as biosimilars increase market penetration.
Frequently Asked Questions
1. How long will NDC 66758-0145 maintain market exclusivity?
Patent protection generally lasts 10-12 years from approval, with exclusivity periods potentially extending through data exclusivity.
2. How does this drug compare to existing therapies in cost?
Pricing is similar to top biologics like Humira, with monthly costs between $6,000 and $7,000.
3. When will biosimilars likely enter the market?
Biosimilar versions are expected around 2028, depending on patent litigation and regulatory approvals.
4. What factors could accelerate price declines?
Early biosimilar approval, payer strategies favoring generics, and regulatory reforms could hasten reductions.
5. How might new clinical data impact pricing strategies?
Positive data extending indications could sustain higher prices; adverse or inconclusive data could lead to price pressures.
References
- IQVIA Institute. (2022). The Use of Biologics in Autoimmune Disease Treatment.
- FDA. (2022). Drug Approval Announcements.
- GoodRx. (2022). Biologic drug pricing data.
- EvaluatePharma. (2022). World Market Outlook – Biological Drugs.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement and pricing policies.
